Wednesday, March, 20, 2019 03:07:07
Category: Pharmaceuticals
Pfizer recently made an announcement confirming that its experimental oral inhibitor, Janus kinase 3 (JAK3) or PF-06651600, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Apparently, the inhibitor is being developed for treating patients suffering from alopecia areata, …
The National Health Service (NHS), the national healthcare system of England, has reportedly made plans to treat young people and children stricken with cancer with a costly yet revolutionary cancer drug, which has enormous potential to transform the way this disease is treated. According to …
Renowned New York-based pharma magnate Pfizer Inc., has reportedly axed two trials of its Domagrozuma antibody. As per sources, the candidate development has been halted on the grounds of its disappointing failure to meet the required efficacy targets. For the uninitiated, the anti-myostatin antibody is …
AstraZeneca along with its global biologics research and development business, MedImmune, has reportedly announced that the phase III trial for anifrolumab has failed to meet its primary goal. As per trusted sources, the complete evaluation of the data is likely to be conducted after the …
Voluntis, a medical intelligence firm that develops advanced digital therapeutics to enhance medications and medical devices, has reportedly announced to extend its collaboration with AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, in a bid to advance oncology treatment technology. The new agreement states that the …
